Pfizer's Lyrica success a boon for Northwestern University endowment

Pfizer’s Lyrica leads drug sales for the company--but it’s also doing big things for another of the med’s developers.

Royalties on the nerve pain and seizure med have powered the endowment at Northwestern University--which helped develop Lyrica--to $10 billion, making it the eighth largest endowment in the U.S., Bloomberg reports.

Lyrica is responsible for about $1.4 billion of that tally, the news service notes.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

The drug has been a strong performer for Pfizer in recent years. It edged out anti-TNF giant Enbrel for the top spot in the pharma giant’s innovative products portfolio, and totted up $3.66 billion in sales last year. Only the Prevnar franchise of vaccines--which hauled in $6.25 billion last year--was a bigger moneymaker for the company.

The Pfizer-Northwestern relationship isn’t an unusual one. Universities increasingly rely on royalty income to fund research, and the pharma industry increasingly relies on--and partners with--academia on early-stage R&D. Princeton University, for one, collected $524 million in licensing income after Eli Lilly cancer therapy Alimta took off.

While Lyrica has been plenty successful, it hasn’t been all smooth sailing for Pfizer with the product. The New York drugmaker last year hit a snag in England when Lyrica lost its IP shield for its original use in seizures. Generics hit the market, despite the fact that Pfizer still had a patent covering Lyrica as a neuropathic pain treatment--and the company threatened to sue doctors who prescribed the knockoffs off-label for pain before a court order backed its case. 

- get more from Bloomberg

Related Articles:
Hospira gives Pfizer big Q2 revenue boost as new brands Ibrance, Xeljanz offset Prevnar fall
Pfizer Q4 beats on Prevnar surge, but 2016 guidance disappoints
Pfizer to cover NHS docs' script-switching costs in latest Lyrica-protecting move
Pfizer's Lyrica team matches the spokesman to the message
Eli Lilly's Alimta gains may cause Princeton pain

Read more on

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…